OriGene’s winning of this grant is rooted in its insightful investment in the novel technology of SISCAPA. In early January, 2014, OriGene announced its strategic intent to work with SISCAPA technology, developed by Dr. Leigh Anderson, to solve the multifaceted challenge of developing antibodies to specific peptides generated by the fragmentation of the target protein. Through its on-going collaboration with the Institute for Systems Biology (ISB) and with the assistance of NCI’s Clinical Proteomic Technologies for Cancer (CPTC) group, OriGene has made rapid advancements in its efforts to produce high quality antibodies for use in SISCAPA assays to every human protein.
“Development of high-affinity anti-peptide antibodies to every human protein for use in SISCAPA technology is critical to the advancement of this multiplexed protein assay technology platform” stated Dr. Donghui Ma, Senior Vice President and Head of Antibody Development at OriGene Technology. “OriGene’s ability to effectively apply its unique capabilities to the challenges of high quality monoclonal antibody development and determination of antibody specificity are perfectly suited to enable researchers to ultimately realize the promise of SISCAPA technology. Through development of this unique class of high quality antibodies in SISCAPA based applications, OriGene will maintain its leadership position as the world’s premiere monoclonal antibody company and expand the roster of effective tools available for antibody based research.”
“High quality and specific antibodies are critical to the successful development, as well as long-term adoption of SISCAPA based assays in studying human disease. The opportunity to expand our collaboration and further support this SBIR contract is a fantastic way to better leverage our collective knowledge to usher in the next paradigm of assays to quantitatively assess proteins” commented Dr. Robert Moritz, Professor and Director of Proteomics Research at ISB.
OriGene is one of the industry’s largest suppliers of monoclonal antibodies to the life science research and global IVD communities through the production of its TrueMAB™ and UltraMAB® Antibody product lines. In 2010 OriGene established one of the world’s largest high-throughput monoclonal antibody development and validation facilities at the Company’s WuXi, China location. Through its SDIX LLC subsidiary based in Newark, DE, the company has established its GMP and ISO13485 certified quality management system and expanded capacity for diagnostic antibody manufacturing.
